ADAM17 and glioblastoma: Furthermore, we analyzed the expression levels of ADAM17 in the three GBM cell lines following TMZ treatment and observed a dose-dependent increase in ADAM17 expression at both the transcript (Figure 1H–J) and protein levels (Figure 1K–M) in all TMZ-treated GBM cell lines, indicating a possible link between ADAM17 levels and TMZ resistance in GBM.